A Study Of MCG In Cardiac Amyloidosis

Last updated: October 16, 2025
Sponsor: Mayo Clinic
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Amyloidosis

Treatment

SandboxAQ CardiAQ Magnetocardiography

Clinical Study ID

NCT07218705
25-005053
  • Ages > 18
  • All Genders

Study Summary

The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

Eligibility Criteria

Inclusion

Inclusion Criteria

  1. Age ≥ 18 years on the date of consent

  2. Ability for participant to comply with study requirements

  3. Written informed consent

Exclusion Criteria

  1. Pregnant or breastfeeding

  2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG

  3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator).

  4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan

  5. Inability to lie down in a supine/inclined position and stay still on the examination bed

  6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: SandboxAQ CardiAQ Magnetocardiography
Phase:
Study Start date:
November 01, 2025
Estimated Completion Date:
November 30, 2027

Connect with a study center

  • Mayo Clinic in Rochester

    Rochester 5043473, Minnesota 5037779 55905
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.